INTRODUCTION

A Race Still Unfinished

FEW SCIENTIFIC ENDEAVORS CAPTURED AS MUCH PUBLIC INTEREST AS THE RACE TO
identify BRCA1, a gene responsible for inherited predisposition to breast and
ovarian cancers. The search culminated in a 1994 Science paper reporting the
isolation of BRCA1 by positional cloning.* Isolation of the related cancer pre-
disposition gene BRCA2 followed soon after.† Twenty years later, the BRCA
genes continue to make headlines, sparking a Supreme Court decision on the
legality of gene patenting and intense debates on the ethics of genetic testing.

In this special section of Science, expert contributors retrace the long and
tortuous path leading to the mapping and identification of the BRCA1 gene;
discuss the ways in which BRCA mutation status has been integrated into the
clinical management of patients in high-risk families; and highlight the role
of the BRCA proteins in preserving the structural and numerical integrity of
chromosomes throughout the cell cycle, a function that may explain their tumor
suppressor activity.

Science’s News team explores many of the issues that have arisen since the
discovery of the BRCA genes. Advances in molecular medicine have brought
new options for treatment and prevention, driving down mortality rates in
wealthy countries. But in poor countries, shut out from these advances, mortal-
ity rates remain disproportionately high. Widespread breast screening has led
to early detection and a new dilemma: whether to aggressively treat noncancer-
ous lesions that may never become invasive or whether to “watch and wait.”
Since 1994, dozens more genes have been found that increase a woman’s risk
of hereditary breast cancer, but by how much is uncertain, confounding already
complicated issues in genetic testing and counseling. Throughout this explosion
of research, advocacy groups have been a powerful force in boosting funding
and shaping the agenda, and they continue pushing for increasingly ambitious,
some say unrealistic, goals.

Clearly much more needs to be done—both more research and better ways
to get existing treatments to women who need them. The discovery of the BRCA
genes was transformative. More than a million women and men have been tested
for BRCA1 and BRCA2 mutations in the past 20 years, and there is no doubt that
the test has saved lives. But mutations in these two genes account for only 5 to
10% of breast cancer cases in the general population, and worldwide, breast
cancer remains the most common and most deadly cancer in women. Is it time
to start a new race?

— PAULA KIBERSTIS AND LESLIE ROBERTS

A Race Still Unfinished
Paula Kiberstis and Leslie Roberts

Science 343 (6178), 1451.
DOI: 10.1126/science.343.6178.1451